Kiniksa Pharmaceuticals International (KNSA) Other Accumulated Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Other Accumulated Expenses for 10 consecutive years, with $20.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Accumulated Expenses rose 11.39% year-over-year to $20.1 million; the trailing twelve-month figure through Jun 2026 stood at $20.1 million (up 11.39% YoY), and the FY2025 full-year result was $22.1 million, up 29.85% from the prior year.
• Other Accumulated Expenses declined to $20.1 million in Q2 2026 per KNSA's latest filing, from $20.7 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $22.2 million in Q1 2022 and bottomed at $4.3 million in Q1 2023.
• Historically, Other Accumulated Expenses has averaged $14.5 million across 5 years, with a median of $15.2 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses sank 80.49% in 2023, then soared 163.66% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $8.4 million in 2022, then retreated by 2.21% to $8.2 million in 2023, then surged by 108.06% to $17.0 million in 2024, then gained by 29.85% to $22.1 million in 2025, then slipped by 9.41% to $20.1 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $20.1 million, $20.7 million, and $22.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.